Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Dana-Farber Cancer Institute

Status and phase: Withdrawn; Phase 2

Conditions: Peritoneal Cancer; Fallopian Tube Cancer; Ovarian Cancer

Treatments: Drug: Olaparib

Study type: Interventional

Funder types: Other

Identifiers

NCT01661868

11-170

Details and patient eligibility

About

This research study is a way of gaining new knowledge about a drug called olaparib in women who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1) or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with the exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from repairing their DNA. In this research study, we are looking to see how well the drug olaparib works in women who have never received a PARP inhibitor for recurrent ovarian cancer as well as those who have received a prior PARP inhibitor and whose cancer has re-grown after receiving that PARP inhibitor.

Full description

Olaparib tablets will be taken twice daily, orally, in treatment cycles lasting 4 weeks.

On days 1, 8, 12 and 22 of the first 2 cycles and day 1 of all other cycles, subjects will have a physical exam, be asked questions about their general health, and specific questions about any problems they might be having and any medications they are taking.

Tumor will be assess by either CT or MRI scan every 2 cycles (every 2 months). Tumor biopsies will be optional in this study. Only participants that have received a PARP inhibitor in the past will be asked to have a biopsy of their tumor.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has recurred following a platinum-based regimen used at initial diagnosis
• Measurable disease
• Estimated life expectancy greater than 16 weeks
• Normal organ and marrow function
• Evidence of non-childbearing status for women of childbearing potential
• Able to swallow oral medication

Exclusion criteria

• Pregnant or breastfeeding
• Prior PARP inhibitor use for another cancer such as breast cancer
• Receiving any other study agents or any other anti-cancer treatment
• Known brain metastases
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• History of a different malignancy unless disease-free for at least 5 years
• Currently experiencing seizures or currently being treated with any anti-epileptic for seizures
• Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy
• Presence of gastrointestinal disorders that, in the investigator's opinion, are likely to interfere with the absorption of olaparib, or with the patient's ability to take regular oral medication

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

PARP Inhibitor Naive

Active Comparator group

Description:

Patients with no prior PARP inhibitor treatment

Treatment:

Drug: Olaparib

Prior PARP Inhibitor

Active Comparator group

Description:

Patients previously treated with a PARP inhibitor other than olaparib

Treatment:

Drug: Olaparib